BCL2 protein keeps their expression in different conditions treatment nevertheless each EML4-ALK cell modells exhibit variable expression. by Richard Junior Zapata Dongo (17912565)

Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models. by Richard Junior Zapata Dongo (17912565)

miR-1247-3p was downregulated in CRC resistant cells. by Dequan Wang (6007007)

Downregulation of miR-1247-3p inhibited apoptosis and reduced chemosensitivity in cells. by Dequan Wang (6007007)

Loewe synergy-antagonism score analysis shows additive and synergistic effects after ALKi and ABT-199 combination treatment. by Richard Junior Zapata Dongo (17912565)

miR-1247-3p was downregulated in tissues of patients with CRC and was associated with prognosis and drug resistance. by Dequan Wang (6007007)

Overexpression of miR-1247-3p promoted apoptosis and inhibited resistance in drug-resistant cells. by Dequan Wang (6007007)

BCL2 antiapoptotic protein exhibits heterogeneous expression in Ba/F3 EML4-ALK^mutants. by Richard Junior Zapata Dongo (17912565)

Ba/F3 EML4-ALK^mutants exhibit variable dose-response to ABT-199 treatment. by Richard Junior Zapata Dongo (17912565)

Variable evaluation and construction of a prognostic nomogram. by Kai Yang (73590)

Coupled gGM and CSF fMRI signal changes induced by a transient hypercapnia challenge. by Juliana Zimmermann (10507091)

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

Transcriptomics Points-of-Departure (tPODs) to Support Hazard Assessment of Benzo[<i>a</i>]pyrene in Early-Life-Stage Rainbow Trout by Alper James Alcaraz (20977320)

“…Benchmark concentration analysis of transcriptomic responses at 4 dph, based on the most sensitive transcriptomic features, yielded tPODs between 0.028 and 0.47 μg/L B[<i>a</i>]P. At 28 dph, Cyp1a1 exhibited significantly increased catalytic activity, with biochemical POD, bPOD_EROD,28dph of 0.599 μg/L B[<i>a</i>]P, while morphometric analysis showed significant growth inhibition in terms of length, with apical POD, aPOD_length,28dph of 1.77 μg/L B[<i>a</i>]P, with a notable decreasing trend in body weight. …”

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)